Participated · Seed · Dec 2025

Founded in 2025, Lucis offers a preventive health platform that analyses more than 110 blood biomarkers and combines those results with longitudinal data and physician-reviewed AI insights to deliver personalised nutrition, supplementation, lifestyle, and follow-up testing recommendations. The company has grown rapidly to over 10,000 users across France, the UK, Ireland, and Portugal and has delivered more than one million biomarker tests. Early outcome data shows that among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication, and more than 80% opted to retest; at initial testing 99.9% had at least one biomarker outside optimal ranges. Lucis operates with a team of about 20 employees, a medical board and a network of 10+ physicians providing clinical oversight. The company plans to expand into Spain, Germany, and Italy by the end of 2026 while continuing to invest in personalisation, longitudinal monitoring, and clinical safety.

Participated · Series A · Aug 2024

Noetik is an AI-native biotechnology company that combines self-supervised machine learning with high-throughput spatial omics and in vivo CRISPR perturbation to discover precision cancer therapies. Its discovery platform pairs human multimodal spatial omics data purpose-built for machine learning with a massively multiplexed in vivo CRISPR Perturb-Map system to train foundation models of tissue and tumor biology. The company has built one of the world’s largest spatial omics-based atlases of human cancer biology and trains multi-modal cancer foundation models such as OCTO. Proceeds from the recent Series A will be used to expand the atlas, scale Perturb-Map throughput, and increase training of its models. Noetik plans to leverage these platform capabilities to advance an innovative pipeline of cancer therapeutics candidates into the clinic and to establish strategic partnerships with academic institutions, health care providers, and pharmaceutical companies. The company is based in San Francisco and recently appointed Shafique Virani as Chief Business Officer to lead partnering efforts. Noetik has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to address fundamental problems in cancer immunology. In under 12 months of operations the company has generated hundreds of terabytes of human data across genomics, transcriptomics, and proteomics to enable foundation models for cell and tissue biology. The company plans to use transformer-based machine learning methods applied to this internal data stack to accelerate target and therapeutics discovery. The recent funding will support substantial internal data generation efforts and continued development of those ML methods. Proceeds will also be used to expand Noetik’s team in machine learning, computational biology, and cancer immunology. Noetik is based in San Francisco and is led by CEO Ron Alfa, with founding leaders including CTO Lacey Padron and CSO Jacob Rinaldi.

Participated · Equity · Apr 2024

LunaJoy Health raised $4.2M to expand its programs and operations across select communities. The company is developing a patient-centered care model designed to address the complex needs of high-risk women. Through its programs LunaJoy aims to improve maternal health care standards for Medicaid mothers. The raise was backed by a group of institutional and venture investors. LunaJoy is led by CEO Sipra Laddha and is based in St. Petersburg, FL. Leadership says the investor support, together with focus on maternal health improvements through TMaH funding, positions the company to drive needed industry change. LunaJoy was founded by psychiatrists Shama Rathi and Sipra Laddha to address gaps in mental healthcare for women. The platform delivers a one-hour biopsychosocial interview to co-create individualized treatment plans and provides personalized care plans for issues across puberty, pregnancy, and menopause. LunaJoy’s model emphasizes earlier screening, detection and preventative care to replace a reactive referral process. The company operates with a distributed team of 15 staff and 25 clinicians. LunaJoy is a Y Combinator graduate and has roots in Tampa and Atlanta. The recent seed funding will be used to expand the workforce, broaden geographic reach, and deepen health system partnerships.

Participated · Equity · Nov 2023

Cocoon Bioscience develops and manufactures specialized enzymes and high-performance growth factors for pharmaceutical, biological-sciences and alternative-protein industries. Its CrisBio® technology automates insect chrysalis systems, using live insects as natural bioreactors to produce enzymes for mRNA synthesis and genetic sequencing and growth factors for cultivated meat at lower cost than other protein-expression platforms. The company says its development significantly reduces production costs and enables industrialization of these biotechnologies. Cocoon offers bespoke, on-demand protein production services and aims to be a long-term partner as customers scale processes and products. Due to strong customer demand, the firm plans to build a new, more efficient manufacturing plant at Parque Tecnológico de Bizkaia in Zamudio to scale CrisBio® to kilogram-per-year production. Proceeds from the financing will be used to expand production capacity, invest in product and process innovation, and strengthen the company. Cocoon Bioscience, born from the split of Algenex after its sale to Insud Pharma in 2022, develops biocomponents including specialized enzymes for mRNA synthesis and genome sequencing and high‑performance growth factors for the alternative‑protein industry. The company also supplies enzymes for the pharmaceutical market. Cocoon’s products target emerging global markets with significant potential. The €15M funding will be used to rapidly scale Cocoon’s platform to industrial levels. Cocoon plans a new production plant in Zamudio (Vizcaya), and when that facility is at full capacity in two to three years the company anticipates revenues of up to €80 million. The financing is intended to accelerate industrialization and commercialization of its enzyme and growth‑factor portfolio.

Participated · Seed · Nov 2021

Zeit Medical offers a wearable early-warning system designed to monitor the brain during sleep and raise alarms if a stroke occurs. The device aims to get people to the hospital faster to mitigate stroke damage and potentially save lives. The company was founded in 2019 and is based in California. Zeit plans to use new funding to expand operations and build its team. It intends to apply for FDA approval for the device. The company has stated the device could be available as early as 2023.